SecBot SecBot
6-K ·Filed Sep 8, 2026

PHVS

Pharvaris N.V.
BULLISH
Impact 8/10
Horizonmonths Processed2mo ago SEC0001193125-26-384339
Notable filing: 6-K
Actionable Insight ▲ Bullish

This is a major derisking event for PHVS. The 83% attack rate reduction with statistical significance across all HAE types, combined with a clean safety profile, positions deucrictibant XR as a potential best-in-class oral prophylactic. Traders should watch for the NDA submission timeline (H1 2027) and potential partnership or M&A interest given the strength of the data across both on-demand and prophylactic formulations. The ongoing CREAATE study for AAE-C1INH provides additional upside optionality.

DirectionBullish
Confidencehigh
Horizonmonths

deucrictibant

◆ Mixed Named in this 6-K
Impact
Phase
Filed/PDUFA (IR capsule); Phase 3 (XR tablet)
Time to market
IR capsule could be approved by April 23, 2027 PDUFA date. XR tablet for prophylaxis would follow later, likely 2028+ if CHAPTER-3 is positive.
Next catalyst
None dated

What to watchTwo binary catalysts in the next ~9 months: CHAPTER-3 topline (Q3 2026) and the PDUFA decision on the IR capsule (April 23, 2027). The bigger swing factor near-term is CHAPTER-3, a positive readout would validate the larger prophylactic market opportunity, while a miss would severely dent the thesis given that sebetralstat (KalVista) already beat deucrictibant to market as the first oral on-demand HAE therapy.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$37.84
T+0 close · Sep 8, 2026 · via day close
Latest settled
−17.76%
T+20 · $31.12 · next T+60 in 15d
Vs SPY
−19.73%
α at T+20
Latest observation
−6.59%
T+48 · FF3 residual α
  1. T+0 · Sep 8 $37.84entry
  2. T+1 · 2mo ago −0.26%α +0.20% · $37.74
  3. T+5 · 2mo ago +2.70%α +3.36% · $38.86
  4. T+20 · 6w ago −17.76%α −19.73% · $31.12
  5. T+49 · todayOpen
  6. T+60 · in 15d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pharvaris announced overwhelmingly positive topline data from the CHAPTER-3 pivotal Phase 3 study of deucrictibant XR for prophylaxis of HAE attacks. The study met its primary endpoint with an 83% attack rate reduction versus placebo (p<0.0001) and all secondary endpoints were met with statistical significance, with a well-tolerated safety profile. This data supports planned NDA submissions starting in the first half of 2027, positioning deucrictibant as a potential first-in-class oral therapy with injectable-like efficacy for both on-demand and prophylactic treatment, which is a transformative event for this late-stage biotech company.

Key Facts

  • Primary endpoint met: 83% attack rate reduction versus placebo (p<0.0001) in all three types of HAE.
  • 87% attack rate reduction versus placebo observed in HAE Type 1 or Type 2 patients.
  • All secondary efficacy endpoints met with statistical significance.
  • Deucrictibant XR was well tolerated with no treatment-related serious adverse events.
  • Marketing authorization applications planned starting in first half of 2027.
  • Ongoing regulatory review of NDA for deucrictibant IR for on-demand treatment.
  • Topline data from CREAATE study for AAE-C1INH anticipated in Q1 2027.

Financial Impact

Transformative pipeline event for a $2.6B market cap biotech; positive Phase 3 data in a large addressable market (HAE prophylaxis) with potential to capture significant market share from injectable therapies. No financial figures provided in the filing.

future_revenuepipeline_valueregulatory_outlook

Risk Factors

  • Regulatory risk: FDA review and potential approval uncertainties remain despite strong data.
  • Commercial execution risk: Launching two products (IR and XR) simultaneously requires significant resources.
  • Competitive risk: Established injectable therapies (Takhzyro, Haegarda) and emerging oral competitors (Orladeyo) exist in the HAE market.
  • Dilution risk: Potential need for additional capital to fund commercial launches and ongoing trials.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001193125-26-384339
Document: 6-k_september_8_2026.htm0001193125-26-384339
Document: 0001193125-26-384339-index-headers.html0001193125-26-384339
Document: 0001193125-26-384339-index.html0001193125-26-384339
Document: 0001193125-26-384339.txt0001193125-26-384339

Track record

51 reports on PHVS

Performance horizon

14 of 17 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 16 of 18 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
  3. Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  4. Nov 12, 20264d ago 6-K Neutral 4/10 No price data
  5. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  6. Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
  7. Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  8. Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  9. Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
  10. Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
Showing 10 of 51

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 9, 2026